Yemin Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yemin Cao has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Yongkang Zhang
8 shared publicationsYuzhen Wang
Pan-Vascular Management Center, Shanghai TCM-Integrative Hospital, Shanghai University of Traditional Chinese Medicine
6 shared publicationsYuan Zong
5 shared publications- Yongkang Zhang
Pan-Vascular Management Center, Shanghai TCM-Integrative Hospital, Shanghai University of Traditional Chinese Medicine
4 shared publications Fang Cao
3 shared publicationsHongcheng Du
Pan-Vascular Management Center, Shanghai TCM-Integrative Hospital, Shanghai University of Traditional Chinese Medicine
3 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1916929
From revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
Peripheral arterial disease (PAD), a critical manifestation of systemic atherosclerosis (AS), poses substantial therapeutic challenges. Despite pharmacological interventions and revascularization, efficacy remains constrained by high restenosis rates and suboptimal functional recovery. These limitations underscore a necessary transition from localized structural revascularization toward integrated systemic repair, with a particular focus on the underlying immunopathology. The progression of PAD is driven by a dysregulated immune response, characterized by an imbalance in macrophage polarization (M1/M2), overactivation of the NLRP3 inflammasome, and a vicious cycle of immune-metabolic coupling. Current research trajectories emphasize the synergistic orchestration of the vascular microenvironment through immunomodulation. Beyond modulating localized inflammatory responses, emerging strategies target metabolic homeostasis and advanced tissue engineering, including spatiotemporal growth factor delivery, extracellular vesicle-based therapies, and bioengineered scaffolding systems. These interdisciplinary developments point toward a multimodal integrated therapeutic strategy for PAD. Such a strategy would build on conventional revascularization and may address its limitations, including restenosis, through targeted immunomodulation and local tissue regeneration. Whether this approach can improve long-term outcomes compared with revascularization alone remains to be tested. If validated, it could shift the clinical standard beyond vessel patency toward comprehensive, long-term vascular health.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1916929
Open AccessFrom revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
Peripheral arterial disease (PAD), a critical manifestation of systemic atherosclerosis (AS), poses substantial therapeutic challenges. Despite pharmacological interventions and revascularization, efficacy remains constrained by high restenosis rates and suboptimal functional recovery. These limitations underscore a necessary transition from localized structural revascularization toward integrated systemic repair, with a particular focus on the underlying immunopathology. The progression of PAD is driven by a dysregulated immune response, characterized by an imbalance in macrophage polarization (M1/M2), overactivation of the NLRP3 inflammasome, and a vicious cycle of immune-metabolic coupling. Current research trajectories emphasize the synergistic orchestration of the vascular microenvironment through immunomodulation. Beyond modulating localized inflammatory responses, emerging strategies target metabolic homeostasis and advanced tissue engineering, including spatiotemporal growth factor delivery, extracellular vesicle-based therapies, and bioengineered scaffolding systems. These interdisciplinary developments point toward a multimodal integrated therapeutic strategy for PAD. Such a strategy would build on conventional revascularization and may address its limitations, including restenosis, through targeted immunomodulation and local tissue regeneration. Whether this approach can improve long-term outcomes compared with revascularization alone remains to be tested. If validated, it could shift the clinical standard beyond vessel patency toward comprehensive, long-term vascular health.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762892
Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations
Background and objectives: Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development. Methods: We analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov , Chinadrugtrials.org , and ISRCTN. Trials were systematically categorized by study phase, geographic distribution, and therapeutic mechanism, with data synthesized to reflect the transition from non-specific immunosuppression to precision-targeted approaches. Key findings: Our analysis indicates an accelerating trend in Phase II/III trials, with a notable geographic shift toward the Asia-Pacific region. We identify a diversification of therapeutic targets beyond B-cell depletion (e.g., obinutuzumab) to include complement inhibitors, intracellular signaling blockers (BTK and JAK inhibitors), and novel immune-reset strategies such as CAR-T therapy. Despite these innovations, complete renal response rates in pivotal trials often plateau at 40-50%, suggesting a persistent “ceiling effect”. Conclusion and implications: To break current therapeutic plateaus, future research must prioritize: (1) integrating pharmacogenomics (e.g., CYP3A5 and TPMT genotyping) for personalized drug selection; (2) developing steroid-fast-tapering or steroid-free induction protocols to minimize toxicity; and (3) validating real-time molecular biomarkers to replace lagging clinical indicators. This data-driven perspective provides a practical framework for refining trial designs and achieving precision medicine in LN.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762892
Open AccessGlobal perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations
Background and objectives: Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development. Methods: We analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov , Chinadrugtrials.org , and ISRCTN. Trials were systematically categorized by study phase, geographic distribution, and therapeutic mechanism, with data synthesized to reflect the transition from non-specific immunosuppression to precision-targeted approaches. Key findings: Our analysis indicates an accelerating trend in Phase II/III trials, with a notable geographic shift toward the Asia-Pacific region. We identify a diversification of therapeutic targets beyond B-cell depletion (e.g., obinutuzumab) to include complement inhibitors, intracellular signaling blockers (BTK and JAK inhibitors), and novel immune-reset strategies such as CAR-T therapy. Despite these innovations, complete renal response rates in pivotal trials often plateau at 40-50%, suggesting a persistent “ceiling effect”. Conclusion and implications: To break current therapeutic plateaus, future research must prioritize: (1) integrating pharmacogenomics (e.g., CYP3A5 and TPMT genotyping) for personalized drug selection; (2) developing steroid-fast-tapering or steroid-free induction protocols to minimize toxicity; and (3) validating real-time molecular biomarkers to replace lagging clinical indicators. This data-driven perspective provides a practical framework for refining trial designs and achieving precision medicine in LN.
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (5) , 434
Four-dimensional CTA detects non-puncture hemorrhage after percutaneous transluminal angioplasty for peripheral arterial disease
Four-dimensional CTA detects non-puncture hemorrhage after percutaneous transluminal angioplasty for peripheral arterial disease
- 1 May 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (5) , 434
Open AccessFour-dimensional CTA detects non-puncture hemorrhage after percutaneous transluminal angioplasty for peripheral arterial disease
Four-dimensional CTA detects non-puncture hemorrhage after percutaneous transluminal angioplasty for peripheral arterial disease
- Open Access
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1700963
Murine hindlimb ischemia models: a narrative review
The murine hindlimb ischemia model is a classical experimental platform for studying peripheral arterial disease (PAD). It primarily includes three categories: acute ischemia models, subacute-to-chronic ischemia models, and ischemia-reperfusion models. Acute ischemia models are the most widely applied, with relatively well-established methodologies. They are typically induced by ligation or electrocauterization, but other approaches such as interventional embolization, photochemical thrombosis, physical injury, chemical injury, and embolization with traditional Chinese medicine-derived microparticles have also been employed. Subacute-to-chronic ischemia models, including the Ameroid constrictor, intravascular suture, anticoagulant silicone tube, and loop techniques, better reflect the pathophysiology of chronic PAD but have not yet been standardized for broad use. Ischemia-reperfusion models, as specialized interventional variants, are increasingly studied in the context of revascularization-related injuries. This review summarizes the methodologies, advantages, and limitations of the above models, and highlights factors influencing model establishment and experimental outcomes, aiming to provide a comprehensive reference for future research using murine hindlimb ischemia models.
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1700963
Open AccessMurine hindlimb ischemia models: a narrative review
The murine hindlimb ischemia model is a classical experimental platform for studying peripheral arterial disease (PAD). It primarily includes three categories: acute ischemia models, subacute-to-chronic ischemia models, and ischemia-reperfusion models. Acute ischemia models are the most widely applied, with relatively well-established methodologies. They are typically induced by ligation or electrocauterization, but other approaches such as interventional embolization, photochemical thrombosis, physical injury, chemical injury, and embolization with traditional Chinese medicine-derived microparticles have also been employed. Subacute-to-chronic ischemia models, including the Ameroid constrictor, intravascular suture, anticoagulant silicone tube, and loop techniques, better reflect the pathophysiology of chronic PAD but have not yet been standardized for broad use. Ischemia-reperfusion models, as specialized interventional variants, are increasingly studied in the context of revascularization-related injuries. This review summarizes the methodologies, advantages, and limitations of the above models, and highlights factors influencing model establishment and experimental outcomes, aiming to provide a comprehensive reference for future research using murine hindlimb ischemia models.
- Open Access
- 8 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1402-1414
Identification of disulfidptosis-related genes in immunity and immunotherapy in diabetic foot ulcer
Background: Diabetic foot ulcer (DFU) is one of the most common and severe complications of diabetes, with vascular changes, neuropathy, and infections being the primary pathological mechanisms. Disulfidptosis, a recently identified form of programmed cell death, might be involved in the development of diabetic complications. This study aims to identify and validate potential disulfidptosis biomarkers associated with DFU through bioinformatics and machine learning analysis. Methods: We downloaded two microarray datasets related to DFU patients from the Gene Expression Omnibus (GEO) database, namely GSE134431, GSE68183, and GSE80178. From the GSE134431 dataset, we obtained differentially expressed Gln-metabolism-related genes (deDRGs) between DFU and normal controls. We analyzed the correlation between deDRGs and immune cell infiltration status. We also explored the relationship between DRG molecular clusters and immune cell infiltration status. Notably, we used Weighted Gene Co-expression Network Analysis (WGCNA) to identify differentially expressed genes within specific clusters. We used Gene Set Variation Analysis (GSVA) to explore which pathways might be related to the DRGs. Subsequently, we constructed and screened the best machine learning model. Finally, we validated the predictions’ accuracy using a nomogram, calibration curves, decision curve analysis, and the GSE80178 and GSE68183 datasets. Results: In both the DFU and normal control groups, we confirmed the presence of deDRGs and an activated immune response. From the GSE134431 dataset, we obtained 33 deDRGs, including MYH10, MYL6, UBASH3B, SLC7A11, DSTN, CD2AP, ME1, OXSM, NDUFC1, GYS1, SCO2, NLN, HNRNPH2, MRPS17, SART3, SAFB2, SAFB, HNRNPU, HNRNPM, MYH14, GTF2I, MYH3, CNOT1, PCBP2, GLUD1, MYH11, TLN2, CHD4, SQSTM1, NDUFB11, NDUFS2, SAMM50, and PPIH. Furthermore, two clusters were identified in DFU. Immune infiltration analysis indicated the presence of immune heterogeneity in these two clusters. Additionally, we established a support vector machine model based on five genes (RALY, R3HCC1, CES1, TCEAL3, and F13A1), which exhibited excellent performance on the external validation datasets GSE80178 and GSE68183 (AUC = 1). Conclusion: This study has identified five disulfidptosis genes associated with DFU, revealing potential novel biomarkers and therapeutic targets for DFU. Additionally, the infiltration of immune-inflammatory cells plays a crucial role in the progression of DFU.
- 8 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1402-1414
Open AccessIdentification of disulfidptosis-related genes in immunity and immunotherapy in diabetic foot ulcer
Background: Diabetic foot ulcer (DFU) is one of the most common and severe complications of diabetes, with vascular changes, neuropathy, and infections being the primary pathological mechanisms. Disulfidptosis, a recently identified form of programmed cell death, might be involved in the development of diabetic complications. This study aims to identify and validate potential disulfidptosis biomarkers associated with DFU through bioinformatics and machine learning analysis. Methods: We downloaded two microarray datasets related to DFU patients from the Gene Expression Omnibus (GEO) database, namely GSE134431, GSE68183, and GSE80178. From the GSE134431 dataset, we obtained differentially expressed Gln-metabolism-related genes (deDRGs) between DFU and normal controls. We analyzed the correlation between deDRGs and immune cell infiltration status. We also explored the relationship between DRG molecular clusters and immune cell infiltration status. Notably, we used Weighted Gene Co-expression Network Analysis (WGCNA) to identify differentially expressed genes within specific clusters. We used Gene Set Variation Analysis (GSVA) to explore which pathways might be related to the DRGs. Subsequently, we constructed and screened the best machine learning model. Finally, we validated the predictions’ accuracy using a nomogram, calibration curves, decision curve analysis, and the GSE80178 and GSE68183 datasets. Results: In both the DFU and normal control groups, we confirmed the presence of deDRGs and an activated immune response. From the GSE134431 dataset, we obtained 33 deDRGs, including MYH10, MYL6, UBASH3B, SLC7A11, DSTN, CD2AP, ME1, OXSM, NDUFC1, GYS1, SCO2, NLN, HNRNPH2, MRPS17, SART3, SAFB2, SAFB, HNRNPU, HNRNPM, MYH14, GTF2I, MYH3, CNOT1, PCBP2, GLUD1, MYH11, TLN2, CHD4, SQSTM1, NDUFB11, NDUFS2, SAMM50, and PPIH. Furthermore, two clusters were identified in DFU. Immune infiltration analysis indicated the presence of immune heterogeneity in these two clusters. Additionally, we established a support vector machine model based on five genes (RALY, R3HCC1, CES1, TCEAL3, and F13A1), which exhibited excellent performance on the external validation datasets GSE80178 and GSE68183 (AUC = 1). Conclusion: This study has identified five disulfidptosis genes associated with DFU, revealing potential novel biomarkers and therapeutic targets for DFU. Additionally, the infiltration of immune-inflammatory cells plays a crucial role in the progression of DFU.
- Open Access
- 12 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3071-3072
Correspondence: Questions on the effects of supplementing extracorporeal shockwave therapy in tendinopathy treatment
An abstract is unavailable. This article is available as a PDF only.
- 12 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3071-3072
Open AccessCorrespondence: Questions on the effects of supplementing extracorporeal shockwave therapy in tendinopathy treatment
An abstract is unavailable. This article is available as a PDF only.
- 2 May 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (2) , 382
Creeping Fat and Muscle Hyperplasia in Crohn’s Disease: A Critical Mechanistic Link for Stricture Formation
- 2 May 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (2) , 382
Creeping Fat and Muscle Hyperplasia in Crohn’s Disease: A Critical Mechanistic Link for Stricture Formation